OREX News Alert Orexigen Therapeutics (OREX) 6.06 01/01/2015

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Orexigen Therapeutics (OREX) 6.06 $OREX

Sell EnteroMedics And Step To The Sidelines
Scientist on Stocks - at Seeking Alpha - Tue Dec 30, 11:25AM CST

OREX: 6.06 (+0.12), ETRM: 1.42 (+0.04), VVUS: 2.88 (+0.10), ARNA: 3.47 (+0.07)

Can High Priced Novo Nordisk Anti-Obesity Injection Make It?
Spencer Osborne - at Seeking Alpha - Mon Dec 29, 12:30PM CST

OREX: 6.06 (+0.12), NVO: 42.32 (-0.35), VVUS: 2.88 (+0.10), ARNA: 3.47 (+0.07)

The Obesity Treatment Market Could Finally Achieve Some Of Its Potential In 2015
Kanak Kanti De - at Seeking Alpha - Mon Dec 29, 12:24PM CST

OREX: 6.06 (+0.12), NVO: 42.32 (-0.35), VVUS: 2.88 (+0.10), ARNA: 3.47 (+0.07)

Arena - Belviq Advertsing Closes Out Year With Big Push
Spencer Osborne - at Seeking Alpha - Mon Dec 29, 12:13PM CST

OREX: 6.06 (+0.12), VVUS: 2.88 (+0.10), ARNA: 3.47 (+0.07)

Is Vivus Headed Towards An Unfortunate Ending?
Alexander Maxwell - at Seeking Alpha - Sat Dec 27, 7:27AM CST

OREX: 6.06 (+0.12), NVO: 42.32 (-0.35), VVUS: 2.88 (+0.10), ARNA: 3.47 (+0.07)

The Newest FDA-Approved Obesity Drug Is Also the Oldest
Brian Orelli, The Motley Fool - Motley Fool - Sat Dec 27, 7:04AM CST
Novo Nordisk  on Tuesday gained Food and Drug Administration approval for its obesity drug Saxenda. While that is not the feat it would have been  a few years ago, Novo Nordisk can boast that its  obesity drug was approved on its first try, unlike ...
OREX: 6.06 (+0.12), NVO: 42.32 (-0.35), AZN: 70.38 (-0.31), VVUS: 2.88 (+0.10), LLY: 68.99 (-0.65), GSK: 42.74 (-0.05), ARNA: 3.47 (+0.07)

3 Stocks Poised for Eye-Popping Gains in 2015
George Budwell, The Motley Fool - Motley Fool - Sat Dec 27, 6:27AM CST
Source: Flicker via 401kcalculator.org The stock market has been on fire since the start of 2012. Biotech companies, though, have posted particularly impressive gains, markedly outperforming the broader markets during this time period. The ...
OREX: 6.06 (+0.12), GILD: 94.26 (-1.02), VVUS: 2.88 (+0.10), IBB: 303.35 (-1.27), ABBV: 65.44 (-0.86), PRTA: 20.76 (+0.07), ARNA: 3.47 (+0.07)

4 Potential Blockbuster Drugs The FDA Just Approved
at Investor's Business Daily - Fri Dec 26, 11:35AM CST
While the approval of AbbVie's (ABBV) hepatitis C regimen Viekira Pak hogged most of the headlines, over the past week the FDA has approved a whole passel of medicines that could be blockbusters for their makers. Here's a short list of some of the...
OREX: 6.06 (+0.12), MYGN: 34.06 (-0.77), NVO: 42.32 (-0.35), CBST: 100.65 (-0.05), AZN: 70.38 (-0.31), MRK: 56.79 (-0.86), VVUS: 2.88 (+0.10), ABBV: 65.44 (-0.86), BMY: 59.03 (-0.36), ARNA: 3.47 (+0.07)

First Week Of February 2015 Options Trading For Orexigen Therapeutics
at The Street - Fri Dec 26, 10:46AM CST
Investors in Orexigen Therapeutics, Inc. saw new options become available this week, for the February 2015 expiration.
OREX: 6.06 (+0.12)

Shares of OREX Up 42.1% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Dec 26, 9:24AM CST
SmarTrend identified an Uptrend for Orexigen Therapeutics (NASDAQ:OREX) on October 17th, 2014 at $4.16. In approximately 2 months, Orexigen Therapeutics has returned 42.07% as of today's recent price of $5.91.
OREX: 6.06 (+0.12)

4 Biotech Stocks that Doubled in 2014 - Analyst Blog
Arpita Dutt - Zacks Investment Research - Fri Dec 26, 8:00AM CST
Promising pipeline candidates, progress on the regulatory front and interesting research platforms helped these 4 biotech stocks stand out in 2014.
ENDP: 72.12 (-0.70), BMRN: 90.40 (+0.07), AMGN: 159.29 (-1.34), MNKD: 5.22 (-0.13), CELG: 111.86 (-1.68), MDVN: 99.61 (+0.72), JNJ: 104.57 (-0.79), OREX: 6.06 (+0.12), ESRX: 84.67 (-1.08), CBST: 100.65 (-0.05), GILD: 94.26 (-1.02), AUXL: 34.38 (-0.26)

Novo Nordisk's Saxenda Gets FDA Nod, Launch in 1H15 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 24, 3:20PM CST
Novo Nordisk's (NVO) Saxenda received FDA approval as the first once-daily human glucagon-like peptide-1 analogue for chronic weight management.
OREX: 6.06 (+0.12), NVO: 42.32 (-0.35), ARNA: 3.47 (+0.07)

Novo Nordisk Enters Anti-Obesity Space With New FDA Approval
Spencer Osborne - at Seeking Alpha - Wed Dec 24, 6:46AM CST

ZFGN: 30.84 (+0.04), OREX: 6.06 (+0.12), NVO: 42.32 (-0.35), VVUS: 2.88 (+0.10), ARNA: 3.47 (+0.07)

FDA clears Novo Nordisk's weight loss drug Saxenda
AP - Tue Dec 23, 3:49PM CST
NEW YORK (AP) — The Food and Drug Administration has approved a Novo Nordisk diabetes drug as a treatment for obesity. It's the first injectable drug approved for weight loss.
OREX: 6.06 (+0.12), VVUS: 2.88 (+0.10), ARNA: 3.47 (+0.07)

FDA clears Novo weight management drug
Seeking Alpha - at Seeking Alpha - Tue Dec 23, 3:05PM CST

OREX: 6.06 (+0.12), NVO: 42.32 (-0.35), VVUS: 2.88 (+0.10), ARNA: 3.47 (+0.07)

Orexigen's Obesity Drug Mysimba Gets CHMP Nod - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 22, 5:10PM CST
The CHMP gave a positive opinion on the approval of Orexigen's (OREX) weight loss drug, Mysimba.
BIIB: 339.45 (-2.74), OREX: 6.06 (+0.12), AMGN: 159.29 (-1.34)

Contrave Prescriptions Still Rising In A Down Week
Clinically Sound Investor - at Seeking Alpha - Mon Dec 22, 2:47PM CST

OREX: 6.06 (+0.12), VVUS: 2.88 (+0.10), ARNA: 3.47 (+0.07)

Orexigen - Contrave Script Numbers Remain Impressive
Spencer Osborne - at Seeking Alpha - Mon Dec 22, 2:31PM CST

OREX: 6.06 (+0.12), VVUS: 2.88 (+0.10), ARNA: 3.47 (+0.07)

Belviq Scripts Dip - Lack Of T.V. Ads Will Impact Next Numbers
Spencer Osborne - at Seeking Alpha - Mon Dec 22, 2:27PM CST

OREX: 6.06 (+0.12), VVUS: 2.88 (+0.10), ARNA: 3.47 (+0.07)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Baccarat's Luxe Campaign Courts the High-End Traveler

Updated Category News Views 5

Shining the Spotlight on a Crystal-Clear Vision When Baccarat decides to cast its net over the high-end travel market, they're not doing it with subtlety. Nope, they're going all out, and why wouldn't they? When you've got a brand that's synonymous with luxury, you have to play the part. Enter Adriana Lima, the supermodel who could probably sell sand in the Maldives if...

Continue Reading
dMY IV Settlement: Investor Rights and Key Dates

Updated Category News Views 4

dMY IV Settlement: What You Need to Know Listen up, folks! If you've got a stake in dMY Technology Group, Inc. IV, there's big news brewing. We're talking class action, settlement talks, and a cool $11 million on the line. Let's crack open what this means for you as a holder of dMY IV Class A common stock during December 2021's whirlwind. Who Can Get a Piece of the...

Continue Reading
Electrolux Trends: Q3 '26 Shows Resilience Amid Challenges

Updated Category News Views 4

Electrolux's Strategic Moves In A Tough Market Electrolux's Q3 2026 paints a gritty picture—yet there's a pulse of resilience underneath the numbers. Net sales bumped up to SEK 33,919m due to a 3.5% organic growth, showing the company's ability to swim through choppy waters. But let's not brush aside the sharp rocks they’re dodging: soaring raw materials and logistics...

Continue Reading
Sunlife's Q3 2026 Results: Market Awaits Key Insights

Updated Category News Views 5

Sunlife Prepares to Unveil Third Quarter Performance Alright, folks, we're spinning the wheel again and betting on Sun Life Financial's (TSX: SLF) third quarter earnings, taking the spotlight on November 4, 2026. Anyone eyeballing this should circle their calendars, tie their shoelaces, and get prepared. Since they're laying out the details after the markets shut, looks...

Continue Reading
Middle East's Premier Jewellery Event: A Game-Changer

Updated Category News Views 4

An Event Gemmed with Strategic Importance The Middle East is about to see its streets glitter even more than usual. Next week, the Jewellery, Gem & Technology in Dubai (JGTD) event rolls into town, packed with brands that’ll drop in like swanky diamonds. We’re talking 300 heavy-duty exhibitors from all corners of the globe, ready to strut their stuff at the DEC Expo...

Continue Reading
Groundbreaking Sale: Lani Automotive Acquires Iowa Dealership

Updated Category News Views 9

A shift in the automotive retail world takes place with Lani Automotive Group's latest move. They've just picked up their first franchised dealership, Mount Pleasant Chevrolet GMC Chrysler Dodge Jeep Ram in Iowa. It's a mouthful, sure, but it packs a punch in terms of potential growth. Why This Sale Stands Out The deal was brokered by Performance Brokerage Services, which...

Continue Reading
Reverie Saigon Triumphs: Triple Acclaims in Global Awards

Updated Category News Views 5

A Celebration Beyond the Ordinary Now, if there's one thing the travel folks adore; it’s a hotel that isn’t just selling beds but an experience—a place where luxury meets soul. The Reverie Saigon in Ho Chi Minh City has snagged not one, but three prestigious accolades, and that’s worth more than just a passing glance. Exceptional Honors Across the Globe You...

Continue Reading
AceMyNursingExams Debuts Versatile Nursing Prep Platform

Updated Category News Views 5

A Digital Lifeline for Nursing Students Nursing students are buried in responsibilities: lectures, clinical rotations, and sometimes even a job to fund the whole marathon. And just when they think they’ve got it handled, boom, a mountain of exams rises up in front of them. AceMyNursingExams gets this, rolling out an online exam prep platform to keep these future...

Continue Reading
World Treadmill Championship: A New Run Begins

Updated Category News Views 7

A Run Like No Other I’ll bet you’ve heard it all when it comes to races—winding city marathons, grueling ultras with rough terrain, and everything in between. But a world championship on treadmills? Now that's a fresh spin! October 23rd, 2026 is when the RUN X™ World Treadmill Championship kicks off, stretching out across the planet in 400 fitness centres...

Continue Reading
Ziihera Extends Survival in Advanced GEA: Big Gains Ahead?

Updated Category News Views 3

A Hard Look at Ziihera's Three-Year Survival Story You know the drill—anytime a new drug pulls weight in the cancer arena, ears perk up. Jazz Pharmaceuticals' recent unveil at the 2026 ESMO Congress caught my attention like a solid run on the NASDAQ. We're looking at Ziihera, tangoing with tislelizumab and chemotherapy, hauling serious results against the nasty fight of...

Continue Reading

Top 5 Most Recently Viewed Articles

Keynote Speakers Announced for 2026 ISPE Aseptic Conference

Updated Category News Views 133

2026 ISPE Aseptic Conference Overview The upcoming 2026 ISPE Aseptic Conference is scheduled to take place in March and will welcome participants both in person and virtually. This important event will gather industry professionals, innovators, and regulators in a forum aimed at advancing the science and application of aseptic processing and sterile manufacturing. Keynote...

Continue Reading
Celebrating Cinema at the 20th China Film Huabiao Awards

Updated Category News Views 602

A Glimpse into the 20th China Film Huabiao Awards The eagerly anticipated 20th China Film Huabiao Awards is around the corner, taking place in a vibrant and artistic atmosphere. This ceremony not only celebrates individual achievements in the film industry but also marks a significant milestone for Chinese cinema, which has seen remarkable growth over the last century....

Continue Reading
Significant Growth in Optimism Coin Pricing and Activity

Updated Category News Views 90

Optimism (OP) Price Jumps Optimism, the OP token, has stepped into the spotlight with a sharp daily move: up 6.48% in the last 24 hours to $1.60. That daily rise builds on a strong week, where OP climbed more than 17.0%, moving from $1.36 to its current level. Placed against its all-time high of $4.84, today’s price sits well below the peak, a reminder of how far the...

Continue Reading
What Investors Should Know About Annaly Capital Management Now

Updated Category News Views 169

Annaly Capital Management's Upcoming Earnings Report Annaly Capital Management (NYSE:NLY) is scheduled to release its quarterly earnings report soon. Investors are eager to find out how the company is performing and what it might mean for future investments. Analysts predict an earnings per share (EPS) of $0.72, and there is hope that the company will not only meet but...

Continue Reading
UBS Group's Remarkable Performance and Growth Over 5 Years

Updated Category News Views 264

UBS Group: A Powerhouse on the Financial Scene In an era where stock performances often leave investors scratching their heads, UBS Group (NYSE: UBS) has carved out a prominent niche with its stellar market growth. Over the past five years, this banking giant has not just weathered economic storms; it’s thrived, boasting an annual growth rate that surpasses the general...

Continue Reading